InsuLine And Johnson & Johnson Sign MOU

February 2, 2015 | According to a “Globes” report, the Israeli company InsuLine has signed a memorandum of understanding with the American healthcare company Johnson & Johnson. According to the MOU, the two companies will cooperate to obtain regulatory approval for InsuLine’s InsuPad, which reduces injected insulin intake speeds in diabetic patients by up to 50 percent. Once and if regulatory approval is obtained, Johnson & Johnson will become the sole distributor for the InsuPad in a number of international locations, namely in Russia and the countries of the former Soviet Union. InsuLine is headed by CEO Michael Netz.